trending Market Intelligence /marketintelligence/en/news-insights/trending/ttcKuj2B94Odo0eM6zn70w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Fitch affirms Allergan's ratings; outlook revised to positive

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Fitch affirms Allergan's ratings; outlook revised to positive

Fitch Ratings affirmed Allergan plc's ratings at BBB- and revised the outlook to positive from stable.

The rating agency said the positive outlook reflects the Botox-maker's strengthening credit metrics. Assuming generic competition for Allergan's eye drug Restasis becomes available in the market before 2019 ends, Fitch expects the company to operate with debt/EBITDA at or below 3.0x beginning 2020.

In addition, Fitch anticipates the Dublin-based pharmaceutical company will remain an active buyer in the M&A field with its steady free cash flow and existing cash balances available to buy targeted growth-oriented assets. The rating agency noted that Allergan's deals will be generally smaller compared to its earlier transactions and will be funded with internally generated liquidity to support a more stable debt leverage profile.

Fitch projects low- to mid-single-digit organic sales growth for Allergan during 2019 to 2020, excluding the negative impact of generic Restasis competition.